TipRanks
Advertisement
Advertisement

AU:NSB Stock Latest News

NeuroScientific Biopharmaceuticals appoints new CFO as Crohn’s program advances
Company AnnouncementsNeuroScientific Biopharmaceuticals appoints new CFO as Crohn’s program advances
14h ago
NSB
NeuroScientific Wins FDA Backing for StemSmart Crohn’s Trial
PremiumCompany Announcements
NeuroScientific Wins FDA Backing for StemSmart Crohn’s Trial
10d ago
NSB
NeuroScientific Taps Southern Star to Run Phase 2 Crohn’s Trial
PremiumCompany Announcements
NeuroScientific Taps Southern Star to Run Phase 2 Crohn’s Trial
22d ago
NSB
NeuroScientific Biopharmaceuticals Sets October 2026 AGM to Review Governance and Board
PremiumCompany Announcements
NeuroScientific Biopharmaceuticals Sets October 2026 AGM to Review Governance and Board
1M ago
NSB
NeuroScientific Sets October AGM, Pushes Digital Access and Proxy Voting
PremiumCompany Announcements
NeuroScientific Sets October AGM, Pushes Digital Access and Proxy Voting
1M ago
NSB
NeuroScientific Biopharmaceuticals Changes External Auditor Ahead of October AGM
PremiumCompany AnnouncementsNeuroScientific Biopharmaceuticals Changes External Auditor Ahead of October AGM
2M ago
NSB
Neuroscientific Biopharmaceuticals Lodges Updated ASX Governance Disclosures
Premium
Company Announcements
Neuroscientific Biopharmaceuticals Lodges Updated ASX Governance Disclosures
2M ago
NSB
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
Premium
Company Announcements
NeuroScientific Biopharmaceuticals Widens Annual Loss Despite Surge in Income
2M ago
NSB
NeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
PremiumCompany Announcements
NeuroScientific Advances StemSmart Crohn’s Program After Promising Patient Results
3M ago
NSB
Neuroscientific Biopharmaceuticals Options Expire Unexercised, Trimming Equity Overhang
PremiumCompany Announcements
Neuroscientific Biopharmaceuticals Options Expire Unexercised, Trimming Equity Overhang
4M ago
NSB
NeuroScientific Extends Insider Escrow as Major Share Block Set for Release
PremiumCompany Announcements
NeuroScientific Extends Insider Escrow as Major Share Block Set for Release
4M ago
NSB
NeuroScientific Director Converts Performance Shares After SAS Milestone
PremiumCompany Announcements
NeuroScientific Director Converts Performance Shares After SAS Milestone
5M ago
NSB
NeuroScientific Issues New ASX Securities Under Disclosure Exemption
PremiumCompany AnnouncementsNeuroScientific Issues New ASX Securities Under Disclosure Exemption
5M ago
NSB
Neuroscientific Biopharmaceuticals Seeks ASX Quotation for 57 Million New Shares
Premium
Company Announcements
Neuroscientific Biopharmaceuticals Seeks ASX Quotation for 57 Million New Shares
5M ago
NSB
NeuroScientific Biopharmaceuticals outlines stem cell strategy for severe Crohn’s disease
Premium
Company Announcements
NeuroScientific Biopharmaceuticals outlines stem cell strategy for severe Crohn’s disease
5M ago
NSB
NeuroScientific Seeks Trading Halt Ahead of Material Program Results
PremiumCompany Announcements
NeuroScientific Seeks Trading Halt Ahead of Material Program Results
5M ago
NSB
NeuroScientific advances StemSmart cell therapy with strong early Crohn’s data and scale-up plans
PremiumCompany Announcements
NeuroScientific advances StemSmart cell therapy with strong early Crohn’s data and scale-up plans
6M ago
NSB
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
PremiumCompany Announcements
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
7M ago
NSB
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
PremiumCompany Announcements
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
8M ago
NSB
NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
PremiumCompany AnnouncementsNeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
9M ago
NSB
NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
Premium
Company Announcements
NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
9M ago
NSB
NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection
Premium
Company Announcements
NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection
11M ago
NSB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >